Scholarlink

Background <p>We assessed the ability of MR-proANP, sST2 and BNP to predict maintenance of sinus rhythm at one year after successful electrical cardioversion of atrial fibrillation.</p> Methods <p>Prospective, multicenter, observational study including patients undergoing electrical cardioversion of persistent AF. MR-proANP, sST2 and BNP were measured in peripheral venous blood before cardioversion. Primary endpoint was the first recurrence of AF during the 12-month follow-up, defined as ECG showing AF, or any AF episode lasting &gt; 30&#xa0;s on 24&#xa0;h holter monitoring.</p> Results <p>We included 61 patients from 12/2017 to 03/2019 with preserved LVEF (≥ 45%), average age was 67.4 ± 7.8&#xa0;years, 46 were males (75.4%). Sinus rhythm was restored in 51 patients (83.6%). In these 51 patients, plasma concentrations of MR-proANP were significantly higher among patients with recurrent AF at 12&#xa0;months than among those without recurrence (314.45 [210.90–342.50] vs 214.50 [138.97–264.72] pmol/L, <i>p</i> &lt; 0.01). There was no difference between groups in terms of sST2 and BNP concentrations. ROC curve analysis identified an MR-proANP threshold of 311.5&#xa0;pmol/L as having the best predictive value for recurrent AF at 12&#xa0;months. By multivariable analysis, MR-proANP &gt; 311.5&#xa0;pmol/L was found to be the sole predictor of AF recurrence (hazard ratio, 4.74; 95% CI, 1.59–14.07), and identified subjects at very high risk of recurrence (positive predictive value = 83.3%).</p> Conclusion <p>Elevated MR-proANP level independently predicts recurrent AF during the year following electrical cardioversion of atrial fibrillation. Our findings warrant confirmation in larger studies.</p> Trial Registration <p>Registered with ClinicalTrials.gov under the identifier NCT03351816 on 2017-11-20.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MR-proANP, sST2, BNP and sinus rhythm maintenance 1 year after electrical cardioversion for atrial fibrillation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月29日

查看全文
  • Marc Badoz,
  • Guillaume Serzian,
  • Baptiste Favoulet,
  • Jean-Marc Sellal,
  • Christian De Chillou,
  • Gabriel Laurent,
  • Fiona Ecarnot,
  • Karine Bardonnet,
  • Marie-France Seronde,
  • François Schiele,
  • Nicolas Meneveau

摘要

Background

We assessed the ability of MR-proANP, sST2 and BNP to predict maintenance of sinus rhythm at one year after successful electrical cardioversion of atrial fibrillation.

Methods

Prospective, multicenter, observational study including patients undergoing electrical cardioversion of persistent AF. MR-proANP, sST2 and BNP were measured in peripheral venous blood before cardioversion. Primary endpoint was the first recurrence of AF during the 12-month follow-up, defined as ECG showing AF, or any AF episode lasting > 30 s on 24 h holter monitoring.

Results

We included 61 patients from 12/2017 to 03/2019 with preserved LVEF (≥ 45%), average age was 67.4 ± 7.8 years, 46 were males (75.4%). Sinus rhythm was restored in 51 patients (83.6%). In these 51 patients, plasma concentrations of MR-proANP were significantly higher among patients with recurrent AF at 12 months than among those without recurrence (314.45 [210.90–342.50] vs 214.50 [138.97–264.72] pmol/L, p < 0.01). There was no difference between groups in terms of sST2 and BNP concentrations. ROC curve analysis identified an MR-proANP threshold of 311.5 pmol/L as having the best predictive value for recurrent AF at 12 months. By multivariable analysis, MR-proANP > 311.5 pmol/L was found to be the sole predictor of AF recurrence (hazard ratio, 4.74; 95% CI, 1.59–14.07), and identified subjects at very high risk of recurrence (positive predictive value = 83.3%).

Conclusion

Elevated MR-proANP level independently predicts recurrent AF during the year following electrical cardioversion of atrial fibrillation. Our findings warrant confirmation in larger studies.

Trial Registration

Registered with ClinicalTrials.gov under the identifier NCT03351816 on 2017-11-20.